The use of certain biologic therapies such as etanercept (a tumor necrosis factor inhibitor) and interleukin-17 (IL-17) antagonists in patients with CIDs is cautioned due to possible increased risk of IBD [16–22]. The gene discussed is IL17A; the disease is inflammatory bowel disease.